No abstract

Estrogen receptor (ER) and insulin‐like growth factor‐1 receptor (IGF‐1R) signaling are implicated in lung cancer progression. Based on their previous findings, the authors sought to investigate whether estrogen and IGF‐1 act synergistically to promote lung adenocarcinoma (LADE) development in mice. LADE was induced with urethane in ovariectomized Kunming mice. Tumor‐bearing mice were divided into seven groups: 17β‐estradiol (E2), E2+fulvestrant (Ful; estrogen inhibitor), IGF‐1, IGF‐1+AG1024 (IGF‐1 inhibitor), E2+IGF‐1, E2+IGF‐1+Ful+AG1024 and control groups. After 14 weeks, the mice were sacrificed, and then the tumor growth was determined. The expression of ERα/ERβ, IGF‐1, IGF‐1R and Ki67 was examined using tissue‐microarray‐immunohistochemistry, and IGF‐1, p‐ERβ, p‐IGF‐1R, p‐MAPK and p‐AKT levels were determined based on Western blot analysis. Fluorescence‐quantitative polymerase chain reaction was used to detect the mRNA expression of ERβ, ERβ2 and IGF‐1R. Tumors were found in 93.88% (46/49) of urethane‐treated mice, and pathologically proven LADE was noted in 75.51% (37/49). In the E2+IGF‐1 group, tumor growth was significantly higher than in the E2 group (p < 0.05), the IGF‐1 group (p < 0.05) and control group (p < 0.05). Similarly, the expression of ERβ, p‐ERβ, ERβ2, IGF‐1, IGF‐1R, p‐IGF‐1R, p‐MAPK, p‐AKT and Ki67 at the protein and/or mRNA levels was markedly higher in the ligand group than in the ligand + inhibitor groups (all p < 0.05). This study demonstrated for the first time that estrogen and IGF‐1 act to synergistically promote the development of LADE in mice, and this may be related to the activation of the MAPK and AKT signaling pathways in which ERβ1, ERβ2 and IGF‐1R play important roles.

Estrogen classically drives lung cancer development via estrogen receptor β (ERβ). However, fulvestrant, an anti-estrogen-based endocrine therapeutic treatment, shows limited effects for non-small cell lung cancer (NSCLC) in phase II clinical trials. G protein-coupled estrogen receptor (GPER), a third estrogen receptor that binds to estrogen, has been found to be activated by fulvestrant, stimulating the progression of breast, endometrial, and ovarian cancers. We here demonstrated that cytoplasm-GPER (cGPER) (80.49 %) and nucleus-GPER (53.05 %) were detected by immunohistochemical analysis in NSCLC samples. cGPER expression was related to stages IIIA-IV, lymph node metastasis, and poorly differentiated NSCLC. Selective agonist G1 and 17β-estradiol (E2) promoted the GPER-mediated proliferation, invasion, and migration of NSCLC cells. Additionally, in vitro administration of E2 and G1 increased the number of tumor nodules, tumor grade, and tumor index in a urethane-induced adenocarcinoma model. Importantly, the pro-tumorigenic effects of GPER induced by E2 were significantly reduced by co-administering the GPER inhibitor G15 and the ERβ inhibitor fulvestrant, as compared to administering fulvestrant alone both in vitro and in vivo. Moreover, the phosphorylation of MAPK and Akt was involved in E2/G1-induced GPER activation. In conclusion, our results indicated that a pro-tumor function of GPER exists that mediated E2-/G1-dependent NSCLC progression and showed better efficiency regarding the co-targeting of GPER and ERβ, providing a rationale for further investigation of anti-estrogen clinical therapy.

The development of advanced transition metal/nitrogen/carbon-based (M/N/C) catalysts with high activity and extended durability for oxygen reduction reaction (ORR) is critical for platinum-group-metal (PGM) free fuel cells but still remains great challenging. In this review, we summarize the recent progress in two typical M/N/C catalysts (atomically dispersed metalnitrogen-carbon (M-N-C) catalysts and carbon-supported metal nanoparticles with N-doped carbon shells (M@NC)) with an emphasis on their potential applications in fuel cells. Starting with understanding the active sites in these two types of catalysts, the representative innovative strategies for enhancing their intrinsic activity and increasing the density of these sites are systematically introduced. The synergistic effects of M-N-C and M@NC are subsequently discussed for those M/N/C catalysts combining both of them. To translate the material-level catalyst performance into high-performance devices, we also include the recent progress in engineering the porous structure and durability of M/N/C catalysts towards efficient performance in fuel cell devices. From the viewpoint of industrial applications, the scale-up cost-effective synthesis of M/N/C catalysts has been lastly briefed. With this knowledge, the challenges and perspectives in designing advanced M/N/C catalysts for potential PGM-free fuel cells are proposed.

We suggest that activation of GPER exerts an inhibitory effect on colonic motility by promoting NO release from myenteric nitrergic nerves. These results raise a possibility that GPER may be involved in mediating the inhibitory effect of estrogen on colonic motor functions, via a non-genomic, neurogenic mechanism.

Insulin-like growth factor 1 receptor (IGF-1R) is important in cancer pathogenesis and progression. While its signaling pathway is an interesting therapeutic target, recent clinical trials have exhibited limited effects; however, significant crosstalks between IGF- 1R and other signaling pathways have garnered increasing attention. These complex networks include interactions between IGF-1R and receptor tyrosine kinases (RTKs), including insulin receptor (IR), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), mesenchymal-epithelial transition factor (MET), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). Furthermore, IGF-1R also is related to steroid hormones, including estrogen receptors alpha and beta (ER! and ER"), androgen receptor (AR), and progesterone receptor (PR). Cumulatively, actions of crosstalk between IGF-1R, and RTKs/steroid hormones promote tumorigenesis, as demonstrated by the effectiveness of recently proposed therapeutic strategies. These therapeutic strategies, primarily pertaining to crosstalk-cotargeting, exhibited notable advantages in overcoming resistance to conventional chemotherapy and conventional endocrine therapy. Furthermore, these techniques offer benefits beyond the limited effects of single- agent targeting previously reported. Thus, the role of crosstalk between IGF-1R and RTKs/steroid hormones, including strategies to block these pathways in combination with recent development in this field, were reviewed and the potential future cancer therapeutics suggested by this rationale were considered.

Heterogeneous catalytic ozonation is a promising advanced oxidation technology for water treatment. In the present work, the surface fluorination of TiO2 catalysts with a high percentage of exposed {001} facets (F-TiO2) were synthesized through a hydrothermal method using tetrabutyl titanate as the precursor and HF as the shape controlling agent. The structural properties of the catalysts were characterized by X-ray diffraction, the Brunauer–Emmett–Teller method, field-emission scanning electron microscopy, and X-ray photoelectron spectroscopy. The sheetlike TiO2 is pure anatase, with ∼75% of highly reactive {001} facets. The surface fluoride of the F-TiO2 nanosheets can be removed by washing with dilute NaOH solution (abbreviated here as OH-TiO2), resulting in a decrease of Ti3+ content and an increase of the specific surface area. The catalytic activity of the samples was evaluated by degradation of oxalic acid in aqueous solution in the presence of ozone. It was found that F-TiO2 facilitated the catalytic ozonation process by comparison with OH-TiO2 and pure TiO2 nanoparticles prepared in pure water. We conclude that the high surface energies of {001} facets and the increased concentration of oxygen vacancies contributed to the enhancement of the ozonation activity of fluorinated TiO2 with dominant {001} facets.

No abstract